Miniatura

Fitxers

679614.pdf (1.33 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2017-11-27

Llicència de publicació

cc by (c) Ramírez et al., 2017
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/118791

First external quality assurance program for bloodstream Real-Time PCR monitoring of treatment response in clinical trials of Chagas disease

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

http://dx.doi.org/10.1371/journal.pone.0188550

Resum

Real-Time PCR (qPCR) testing is recommended as both a diagnostic and outcome measurement of etiological treatment in clinical practice and clinical trials of Chagas disease (CD), but no external quality assurance (EQA) program provides performance assessment of the assays in use. We implemented an EQA system to evaluate the performance of molecular biology laboratories involved in qPCR based follow-up in clinical trials of CD. An EQA program was devised for three clinical trials of CD: the E1224 (NCT01489228), a pro-drug of ravuconazole; the Sampling Study (NCT01678599), that used benznidazole, both conducted in Bolivia; and the CHAGASAZOL (NCT01162967), that tested posaconazole, conducted in Spain. Four proficiency testing panels containing negative controls and seronegative blood samples spiked with 1, 10 and 100 parasite equivalents (par. eq.)/mL of four Trypanosoma cruzi stocks, were sent from the Core Lab in Argentina to the participating laboratories located in Bolivia and Spain. Panels were analyzed simultaneously, blinded to sample allocation, at 4-month intervals. In addition, 302 random blood samples from both trials carried out in Bolivia were sent to Core Lab for retesting analysis. The analysis of proficiency testing panels gave 100% of accordance (within laboratory agreement) and concordance (between laboratory agreement) for all T. cruzi stocks at 100 par. eq./mL; whereas their values ranged from 71 to 100% and from 62 to 100% at 1 and 10 par. eq./mL, respectively, depending on the T. cruzi stock. The results obtained after twelve months of preparation confirmed the stability of blood samples in guanidine-EDTA buffer. No significant differences were found between qPCR results from Bolivian laboratory and Core Lab for retested clinical samples. This EQA program for qPCR analysis of CD patient samples may significantly contribute to ensuring the quality of laboratory data generated in clinical trials and molecular diagnostics laboratories of CD.

Matèries

Malaltia de Chagas, Biologia molecular

Matèries (anglès)

Chagas' disease, Molecular biology

Citació

Col·leccions

Articles publicats en revistes (ISGlobal)
Articles publicats en revistes (Medicina)

Citació

PARRADO, Rudy, SULLEIRO, Elena, BARRA, Anabelle de la, RODRÍGUEZ, Marcelo, VILLARROEL, Sandro, IRAZU, Lucía, ALONSO VEGA, Cristina, ALVES, Fabiana, CURTO, María a., GARCÍ­A, Lineth, ORTIZ, Lourdes, TORRICO, Faustino, GASCÓN I BRUSTENGA, Joaquim, FLEVAUD, Laurence, MOLINA, Israel, RIBEIRO, Isabela, SCHIJMAN, Alejandro g.. First external quality assurance program for bloodstream
                Real-Time PCR monitoring of treatment response in clinical
                trials of Chagas disease. _PLoS One_. 2017. Vol. 12, núm. 11, pàgs. e0188550. [consulta: 21 de gener de 2026]. ISSN: 1932-6203. [Disponible a: https://hdl.handle.net/2445/118791]

Exportar metadades

JSON - METS

Compartir registre